@article{TCR414,
author = {Stephanie B Wheeler and Katherine Reeder-Hayes and Anne-Marie Meyer},
title = {A balancing act for breast cancer? Everolimus for hormone receptor positive patients},
journal = {Translational Cancer Research},
volume = {1},
number = {2},
year = {2012},
keywords = {},
abstract = {Recent results from a Phase III randomized trial comparing everolimus [a mammalian target of rapamycin (mTOR) inhibitor] plus exemestane versus placebo plus exemestane provide encouraging evidence of a new option for treatment of advanced, hormone receptor positive (HR+) breast cancer (1). Oral endocrine therapy (ET) is the first line therapeutic strategy of choice for most women with metastatic HR+, Her2 negative breast cancer (2).},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/414}
}